[Metastatic renal cell carcinoma: Management of toxicities of combinations]

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Metastatic renal cell carcinoma (mRCC) treatment has advanced with new combination therapies.
• Tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) combinations offer improved efficacy over sunitinib in first-line mRCC.
• The safety profiles and adverse event (AE) management strategies for TKI/ICI combinations are less established than for dual ICI therapies.

Purpose of the Study:

• To analyze safety data from Phase III trials of TKI/ICI and dual ICI combinations in first-line mRCC.
• To provide clinicians with practical guidance for managing adverse effects associated with these novel combination therapies.
• To differentiate AE causality between TKIs and ICIs to inform treatment decisions.

Main Methods:

• Review of safety data from pivotal Phase III clinical trials comparing TKI/ICI or dual ICI regimens against sunitinib in first-line mRCC.
• Analysis of AE incidence, severity (grade), and attribution to specific drug classes (TKI vs. ICI).
• Development of a management algorithm based on AE type, grade, and response to interventions.

Main Results:

• Management strategies for TKI/ICI combinations differ significantly based on AE grade and type.
• Discontinuation of both TKI and ICI is considered from Grade 2 AEs.
• AEs rapidly improving with TKI withdrawal suggest TKI causality, allowing potential reintroduction of TKI (at lower dose) and continuation of ICI.

Conclusions:

• Effective management of TKI/ICI combination toxicities hinges on prompt AE assessment and attribution.
• Specific AEs like cardiac or neurological toxicity require immediate discontinuation and potential hospitalization/corticosteroids from Grade 1.
• Patient education and clear management protocols are crucial for optimizing safety in TKI/ICI-treated mRCC patients.